Ralf Lutterbuese
Overview
Explore the profile of Ralf Lutterbuese including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
821
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Friedrich M, Raum T, Lutterbuese R, Voelkel M, Deegen P, Rau D, et al.
Mol Cancer Ther
. 2012 Oct;
11(12):2664-73.
PMID: 23041545
For treatment of patients with prostate cancer (PCa), we developed a novel T cell-engaging (BiTE) antibody designated AMG 212 or BAY2010112 that is bispecific for prostate-specific membrane antigen (PSMA) and...
2.
Topp M, Kufer P, Gokbuget N, Goebeler M, Klinger M, Neumann S, et al.
J Clin Oncol
. 2011 May;
29(18):2493-8.
PMID: 21576633
Purpose: Blinatumomab, a bispecific single-chain antibody targeting the CD19 antigen, is a member of a novel class of antibodies that redirect T cells for selective lysis of tumor cells. In...
3.
Lutterbuese R, Raum T, Kischel R, Hoffmann P, Mangold S, Rattel B, et al.
Proc Natl Acad Sci U S A
. 2010 Jul;
107(28):12605-10.
PMID: 20616015
Epidermal growth factor receptor (EGFR)-specific monoclonal antibodies predominantly inhibit colorectal cancer (CRC) growth by interfering with receptor signaling. Recent analyses have shown that patients with CRC with mutated KRAS and...
4.
Amann M, dArgouges S, Lorenczewski G, Brischwein K, Kischel R, Lutterbuese R, et al.
J Immunother
. 2009 Jul;
32(5):452-64.
PMID: 19609237
muS110 is a BiTE antibody bispecific for murine EpCAM (CD326) and murine CD3. MT110, its human-specific analog, is in a clinical phase 1 trial for treatment of patients with adenocarcinoma...
5.
Lutterbuese R, Raum T, Kischel R, Lutterbuese P, Schlereth B, Schaller E, et al.
J Immunother
. 2009 Apr;
32(4):341-52.
PMID: 19342971
Carcinoembryonic antigen (CEA, CD66e) is a well-characterized tumor-associated antigen that is frequently overexpressed in tumors. Phospholipases release CEA from tumor cells resulting in high circulating serum levels of soluble CEA...
6.
dArgouges S, Wissing S, Brandl C, Prang N, Lutterbuese R, Kozhich A, et al.
Leuk Res
. 2008 Oct;
33(3):465-73.
PMID: 18835037
We have compared the cytotoxic activity of rituximab with that of blinatumomab (MT103/MEDI-538), a single-chain CD19-/CD3-bispecific antibody engaging human T cells. Blinatumomab consistently led to a higher degree of lysis...
7.
Amann M, Brischwein K, Lutterbuese P, Parr L, Petersen L, Lorenczewski G, et al.
Cancer Res
. 2008 Jan;
68(1):143-51.
PMID: 18172306
EpCAM (CD326) is one of the most frequently and highly expressed tumor-associated antigens known and recently has also been found on cancer stem cells derived from human breast, colon, prostate,...
8.
Hammond S, Lutterbuese R, Roff S, Lutterbuese P, Schlereth B, Bruckheimer E, et al.
Cancer Res
. 2007 Apr;
67(8):3927-35.
PMID: 17440108
The EphA2 receptor tyrosine kinase is frequently overexpressed and functionally altered in malignant cells and thus provides opportunities for selective targeting of tumor cells. We describe here the development of...
9.
Brischwein K, Schlereth B, Guller B, Steiger C, Wolf A, Lutterbuese R, et al.
Mol Immunol
. 2005 Sep;
43(8):1129-43.
PMID: 16139892
We have developed a novel single-chain Ep-CAM-/CD3-bispecific single-chain antibody construct designated MT110. MT110 redirected unstimulated human peripheral T cells to induce the specific lysis of every Ep-CAM-expressing tumor cell line...
10.
Schlereth B, Fichtner I, Lorenczewski G, Kleindienst P, Brischwein K, da Silva A, et al.
Cancer Res
. 2005 Apr;
65(7):2882-9.
PMID: 15805290
Bispecific T-cell engager (BiTE) are a class of bispecific single-chain antibodies that can very effectively redirect cytotoxic T cells for killing of tumor target cells. Here, we have assessed the...